A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs
What this study shows
A short 10-week course of low-dose rapamycin improved heart function measures in healthy pet dogs with no clinical side effects.
At a glance
| Evidence type | A Animal model Marked A because it is an animal intervention or observation study measuring an organismal outcome (model: Companion dogs (client-owned, RCT)); the code names the system studied -- animal work can be rigorous and still not be human data. |
| Study type | 4 - Animal Study |
| Model system | Companion dogs (client-owned, RCT) |
| Journal | GeroScience |
| Year | 2017 |
| Peer reviewed | Yes |
| Record last updated | 2026-08-22 |
| Source | DOI 10.1007/s11357-017-9972-z · PMID 28374166 · Free full text (PMC5411365) |
Extracted findings
| Intervention | Rapamycin (short-term) |
| Target | mTOR |
| Model | Companion dogs (client-owned RCT, n=24) |
| Effect | Short-term rapamycin was well tolerated in middle-aged dogs, with signs of improved cardiac function |
In the Atlas
Related topics
More studies on this topic
- Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice (2016)
- Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster (2010)
- Late-life rapamycin treatment reverses age-related heart dysfunction (2013)
- Association of rapamycin treatment with the modulation of purine metabolism, reduced microglial inflammatory responses, improved mitochondrial energy metabolism, and alleviation of fatigue symptoms in ME/CFS subjects: pilot findings from phase-II observational study (2026)
Learn the biology
Want to understand the biology behind this study? → How to Read an mTOR Paper